Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG changes after single-session psilocybin or MDMA in depression and PTSD
ACTRN12622000883718Phase 3Withdrawn
- Sponsor
- Monarch Mental Health Group
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of psilocybin and midomafetamine in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), sponsored by Monarch Mental Health Group. Primary endpoints: EEG N100 during latent inhibition task, EEG N100 during auditory oddball task and 1 more. Planned start Aug 2022; status: withdrawn.
02
Drugs
psilocybinmidomafetamine
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12622000883718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000883718.